Literature DB >> 11468155

Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin.

J Seppen1, S C Barry, B Harder, W R Osborne.   

Abstract

A lentivirus pseudotyped with vesicular stomatitis virus G protein (VSV-G) encoding rat erythropoietin (EPO) complementary DNA was administered to rat skeletal muscle and red blood cell production was serially monitored. After a single intramuscular injection hematocrit values increased and reached a plateau at about 35 days and were sustained for at least 14 months. Virus doses of 6 x 10(7) infectious units and 6 x 10(6) infectious units produced significantly increased mean hematocrit values of 68.5% +/- 2.1% (P <.001, n = 4) and 52.7% +/- 1.3% (P <.001, n = 3), respectively, over values of control animals receiving normal saline (46.2% +/- 1.5%, n = 2). A polymerase chain reaction (PCR) assay for vector sequences in genomic DNA showed muscle tissue at the site of injection was positive and undetectable in liver, spleen, kidney, and lung. The intramuscular administration of lentivirus provided a dose-responsive, highly efficient and sustained EPO gene delivery, suggesting these vectors may be applied generally to the systemic delivery of proteins such as hormones and clotting factors. (Blood. 2001;98:594-596)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468155     DOI: 10.1182/blood.v98.3.594

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Gene therapy targeting kidney diseases: routes and vehicles.

Authors:  Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

2.  Biological pacing by gene and cell therapy.

Authors:  G J J Boink; J Seppen; J M T de Bakker; H L Tan
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

3.  Repeated lentivirus-mediated granulocyte colony-stimulating factor administration to treat canine cyclic neutropenia.

Authors:  Ofer Yanay; David C Dale; William R A Osborne
Journal:  Hum Gene Ther       Date:  2012-09-12       Impact factor: 5.695

4.  Separating lentiviral vector injection and induction of gene expression in time, does not prevent an immune response to rtTA in rats.

Authors:  David M Markusic; Dirk R de Waart; Jurgen Seppen
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

5.  Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression.

Authors:  En Kimura; Sheng Li; Paul Gregorevic; Brent M Fall; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

6.  Expression of exogenetic enhanced green fluorescent protein in rat endocranium through lentivirus infection.

Authors:  Qi Zhang; Qiang Li; Li Li; Zhaolong Zhang; Yina Wu; Yi Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

7.  The aging of elite male athletes: age-related changes in performance and skeletal muscle structure and function.

Authors:  John A Faulkner; Carol S Davis; Christopher L Mendias; Susan V Brooks
Journal:  Clin J Sport Med       Date:  2008-11       Impact factor: 3.638

8.  A lentiviral gene therapy strategy for the in vitro production of feline erythropoietin.

Authors:  Natalia Vapniarsky; Michael Lame; Samantha McDonnel; Brian Murphy
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

9.  Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.

Authors:  Hongjie Wang; Zong-Yi Li; Ying Liu; Jonas Persson; Ines Beyer; Thomas Möller; Dilara Koyuncu; Max R Drescher; Robert Strauss; Xiao-Bing Zhang; James K Wahl; Nicole Urban; Charles Drescher; Akseli Hemminki; Pascal Fender; André Lieber
Journal:  Nat Med       Date:  2010-12-12       Impact factor: 53.440

Review 10.  Obesity genetics in mouse and human: back and forth, and back again.

Authors:  Fereshteh T Yazdi; Susanne M Clee; David Meyre
Journal:  PeerJ       Date:  2015-03-24       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.